ANI PHARMACEUTICALS INC — Director's Dealing 2018

Mar 5, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ANI PHARMACEUTICALS INC (ANIP)
CIK: 0001023024
Period of Report: 2018-03-01

Reporting Person: PRZYBYL ARTHUR (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-03-01	Common Stock	M	9375	$40.59	Acquired	219358	Direct
2018-03-01	Common Stock	M	6375	$33.00	Acquired	225733	Direct
2018-03-01	Common Stock	M	8236	$6.36	Acquired	233969	Direct
2018-03-01	Common Stock	S	11326	$60.59	Disposed	222643	Direct
2018-03-01	Common Stock	S	8400	$61.62	Disposed	214243	Direct
2018-03-01	Common Stock	S	4260	$62.17	Disposed	209983	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-03-01	Stock Option	$40.59	M	9375	Disposed	2026-04-06	Common Stock (9375)	Direct
2018-03-01	Stock Option	$33.00	M	6375	Disposed	2024-03-31	Common Stock (6375)	Direct
2018-03-01	Stock Option	$6.36	M	8236	Disposed	2023-07-11	Common Stock (8236)	Direct

Footnotes

F1: This transaction was executed in multiple trades at prices ranging from $60.00 to $60.98. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F2: This transaction was executed in multiple trades at prices ranging from $61.00 to $61.99. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3: This transaction was executed in multiple trades at prices ranging from $62.00 to $62.525. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F4: The options vest and become exercisable in equal annual amounts over a four-year period beginning on the first anniversary of the grant date. The grant date was April 7, 2016.

F5: The options vested and become exercisable in equal annual amounts over a four-year period beginning on the first anniversary of the grant date. The grant date was April 1, 2014.

F6: The options vested and become exercisable in equal annual amounts over a four-year period beginning on the first anniversary of the grant date. The grant date was July 12, 2013.